Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch Delivering psilocybin via microneedle patch unlocks potential for...
PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch Focusing on...
PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products Leading U.S.-based CDMO to manufacture...
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome Achieving its second FDA orphan drug...
PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund TORONTO, September 21, 2021 -- InvestorsHub...
PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022 10 clinical sites...
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis Focusing on becoming a global leader in...
PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation Strengthens position to...
PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression Potential...
PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's Disease TORONTO, May 25, 2021...
PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson's Disease TORONTO, May 17, 2021 -- InvestorsHub NewsWire...
PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with...
PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial Evaluating Ketamine in the Treatment of...
PharmaTher Provides Update on Psychedelic Product Programs TORONTO, Canada -- April 15, 2021 -- InvestorsHub NewsWire -- PharmaTher...
PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig's...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관